The ‘Double’ Call in Human Genome (HGSI)
Human Genome Sciences Inc. (NASDAQ: HGSI) is not getting much of a boost despite being called as stock which could manage to double in price over the next 18 months by Barron’s. Usually such…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 326Get Ready for a Pfizer Dividend Hike… A Holiday Gift From Big Pharma (PFE, MRK, WPI, TEVA)
We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks and months ahead. Among those we expect to raise the dividend is Pfizer Inc.…
Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)
AuthorDendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment. Unfortunately, PROVENGE sales ran slower than expected after the FDA took forever to approve it and after…
Winners as Pfizer Loses Lipitor Patent (PFE, TEVA, MYL, WPI)
Pfizer Inc. (NYSE: PFE) has a big day ahead of it. While it has been known for years, it is a massive date: Lipitor goes off-patent and will have generic versions of the statin…
Sequenom Files To Raise Capital (SQNM)
Sequenom, Inc. (NASDAQ: SQNM) has just filed to raise up to $150 million in a mixed securities shelf offering. The diagnostics company could sell any combination of Common Stock, Preferred Stock, Debt Securities, and/or…
Probing for Value in Big Pharmaceutical Stocks (JNJ, PFE, AZN, BMY, MRK)
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie business, a…
Another Bump Up for Dendreon and PROVENGE (DNDN)
Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the infusion costs associated with the administration of PROVENGE. Dendreon noted that this new coverage…
Gilead Paying Up (too much) for Pharmasset (GILD, VRUS)
Gilead Sciences Inc. (NASDAQ: GILD) is trading lower on news that it is spending some $11 billion to buy Pharmasset, Inc. (NASDAQ: VRUS). What is interesting is that Pharmasset was valued only at $5.5…
Dendreon Buyout, How Imminent?
Though near-term growth visibility for its cancer vaccine Provenge remains cloudy, Seattle-based Dendreon (DNDN) could be an attractive takeover candidate – especially to a major pharmaceutical house seeking a unique oncology platform. Consensus on…
America’s Psychiatric Drug Addition
“Sell crazy someplace else; we’re all stocked up here,” says Jack Nicholson in 1997’s As Good as It Gets. There was a point, not so many years ago, when Prozac did not exist, and…
Walmart Denies Plans for Health Care Network, Even as Clinics Thrive
Walmart (NYSE: WMT) said that the press was mistaken when several media reported the world’s largest retailer would create a national medical clinic system within its stores. The denial hardly matters. Walmart is already on…
Vertex RA Study: When Good Is Not Good Enough (VRTX)
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) might have sounded as though shares would be up Monday morning if you were just looking at news over the weekend. Instead, shares are down substantially for a day…
The Eight Drug Shortages Putting Americans at Risk
President Obama this week signed an executive order directing federal regulators to address shortages of vital prescription drugs. According to the president, the order, which does not need congressional approval, was necessary to reduce…
Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN)
Medivation, Inc. (NASDAQ: MDVN) is today’s darling in biotech and emerging pharmaceuticals. It and partner Astellas in Japan showed very positive data on its prostate cancer drug candidate. Its shares are up more than…
Economics of Painkiller Abuse
The regions of the U.S. in which painkiller use is extremely high also tend to be the poorest sections of the nation. Some of the reasons for this are not hard to fathom. Painkillers…